Catheter Precision, Inc. Common Stock (VTAK)
Healthcare › Surgical & Medical Instruments & Apparatus
Price History
Feb 9, 2026 — Aug 16, 2026Investment Snapshot
- P/B of 0.23 — trading below book value
- Piotroski F-Score 3/9 — signs of financial weakness
- Loss-making — negative ROE of -70.2%
- Revenue growing at 95% annually
Catheter Precision, Inc. Common Stock (VTAK) is a Healthcare company operating in Surgical & Medical Instruments & Apparatus, listed on the AMEX , with a market capitalisation of $4 million . Key value metrics: P/B ratio 0.23, Piotroski F-Score 3 out of 9 .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 5 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
Catheter Precision, Inc. Common Stock — Fundamental Analysis Summary
On financial health, VTAK shows a weak Piotroski F-Score of 3/9, a signal of deteriorating financial health, and negative return on equity of -70.2% (sector average: -20.1%), and manageable leverage with a debt-to-equity ratio of 0.55.
StockPik's composite Value Score for VTAK is 47/100 — reflecting current market or financial concerns. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
VTAK reports a solid gross margin of 47.3% (sector average: 37.4%) and a negative operating margin of -740.1%.
VTAK shows revenue growing at 95% year-over-year, with earnings declining at 3%.